BSEBoard Meeting5d ago · 26 Oct 2026, 06:50 pm

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, November 3, 2026 to consider, approve and take on record the unaudited financial results for the quarter and half year ended September 30, 2026.

Pfizer Ltd · 500680

✦ AI SummaryResults

Pfizer Ltd has scheduled a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Pfizer Ltd - 500680 - Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.

Attachments (1)

📄

53f0bd96-4e4d-4e37-9113-6bea5cee1521.pdf

pdf

Download →
View document text
Pfizer Limited The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274 October 26, 2026 The Corporate Relationship Dept. The Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1st Floor, P.J.Towers Exchange Plaza, 5th Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER Dear Sirs / Madam, Sub: Board Meeting to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026. Ref.: Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, November 3, 2026, inter alia, to consider, approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. Further, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and in accordance with “Pfizer Limited – Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders”, the Trading Window for dealing in shares of the Company shall continue to remain closed until the expiry of 48 hours after the said financial results are made public. Request you to please take the above on record. Thanking you, Yours truly, For Pfizer Limited Prajeet Nair Director – Corporate Services & Company Secretary Cc: National Securities Depository Limited (NSDL) Central Depository Services (India) Limited (CDSL) KFin Technologies Limited CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in